Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.

Breast cancer research and treatment - 1 Jan 2016

Liang Diana H, Ensor Joe E, Liu Zhe-Bin, Patel Asmita, Patel Tejal A, Chang Jenny C, Rodriguez Angel A

Abstract excerpt

Due to the spatial and temporal genomic heterogeneity of breast cancer, genomic sequencing obtained from a single biopsy may not capture the complete genomic profile of tumors. Thus, we propose that cell-free DNA (cfDNA) in plasma may be an alternate source of genomic information to provide comprehensive data throughout a patient's clinical course. We performed a retrospective chart review of 100 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to ErbB Receptors

Share to Gene Amplification

Share to Neoplasm Staging

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 26667234
DOI: 10.1007/s10549-015-3635-5

Genes

EGFR
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.PMID 26667234Read ↗

The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer.Semantic proximity Read ↗

Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.Semantic proximity Read ↗

Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.Semantic proximity Read ↗

The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients.Semantic proximity Read ↗

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.Semantic proximity Read ↗

High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.Semantic proximity Read ↗

Use of cell free DNA in breast oncology.Semantic proximity Read ↗

The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring.Semantic proximity Read ↗

Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging TechnologiesSemantic proximity Read ↗

Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer.Semantic proximity Read ↗

Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast CancerSemantic proximity Read ↗

Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.